Dynavax Technologies Corporation reaffirmed financial guidance for the full year 2024. For the year, the company expects HEPLISAV-B net product revenue between approximately $265 million - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.32 USD | +1.78% | +4.06% | -12.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.02% | 1.58B | |
+18.49% | 125B | |
+14.75% | 109B | |
-3.34% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.04% | 16.67B | |
-13.17% | 16.64B | |
+1.39% | 13.45B | |
+23.33% | 11.32B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024